104
Participants
Start Date
January 7, 2021
Primary Completion Date
February 15, 2023
Study Completion Date
May 23, 2023
Ulixertinib
Oral, 600 mg, twice daily, for 28-days in each treatment cycle
Physician's Choice
Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
Columbia University Irving Medical Center, New York
Montefiore Medical Center, The Bronx
UPMC Hillman Cancer Center, Pittsburgh
Christiana Care Health Services / Helen F. Graham Cancer Center, Newark
Johns Hopkins Sibley Memorial Hospital, Washington D.C.
Virginia Cancer Specialists, PC, Fairfax
Duke University Medical Center / Duke Cancer Institute, Durham
Mayo Clinic, Jacksonville
University of Florida, Gainesville
Tennessee Oncology, PLLC - Sarah Cannon (SCRI), Nashville
Kettering Cancer Center, Kettering
University of Wisconsin Clinical Science Center, Madison
Marshfield Medical Center, Marshfield
Metro-Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park
Mayo Clinic, Rochester
Avera Cancer Institute, Sioux Falls
Washington University School of Medicine - Siteman Cancer Center, St Louis
MD Anderson Cancer Center, Houston
Mayo Clinic, Phoenix
Hoag Memorial Hospital Presbyterian, Newport Beach
University of Washington/Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Lead Sponsor
BioMed Valley Discoveries, Inc
INDUSTRY